par
Medicine top-ups to be allowed
November 5, 2008Sales and Marketing NICE, par
The ban on NHS patients using top-up payments to receive privately-prescribed medicines has been lifted in a move aimed at …
PPRS talks stall
October 22, 2008Sales and Marketing par
Talks on the future of pharmaceutical pricing scheme the PPRS have stumbled into trouble, after it emerged a major part …
Latest news from Datamonitor
September 29, 2008Sales and Marketing par
Is cost containment impacting pharmaceutical innovation?With the cost of healthcare provision spiraling, governments and payers across the seven major markets …
Ban on ‘top-up’ payments for drugs not working
September 18, 2008Sales and Marketing NHS, par
The King's Fund says the current ban on NHS patients paying privately for 'top-up' drugs is not working. The Department …
GSK seeks risk-sharing deal for Tyverb
September 17, 2008Sales and Marketing Cancer, GSK, NICE, par
GlaxoSmithKline has approached the government for a new pricing deal on its breast cancer drug Tyverb, which could make it …
Postcode lottery of care persists in England
September 11, 2008Sales and Marketing par
A new report identifies widespread variations in how much the NHS spends locally on different diseases. The King's Fund says …
Relief as pharma industry secures ‘pro-innovation’ UK pricing deal
July 16, 2008Sales and Marketing ABPI, par
Agreement has been reached on a new UK medicines pricing deal which safeguards the industry's ability to set its own …
Government remains tight-lipped on PPRS
February 29, 2008Sales and Marketing par
The Department of Health has refused to comment on renewed speculation on the future of the UK's medicines pricing system …
Tough talking ahead as government signals end to UK medicines pricing deal
August 2, 2007ABPI, par
The government has told the UK pharmaceutical industry it wants to talk about the future of medicines pricing in the …
Abbott lowers prices on HIV drugs
April 12, 2007Sales and Marketing HIV, par
Intervention from the World Health Organisation has spurred Abbott to lower its prices on HIV drugs in developing countries.The company …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
